For context, in PACE, 66% and 70% of patients with T315I-mutated CML-CP receiving ponatinib 45 mg QD, the recommended starting dose, achieved CCyR by 12 and 57 months, respectively [13, 18, 35]. The gene discussed is CP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.